Within druggable target space, new small-molecule modalities, particularly covalent
inhibitors and targeted degraders, have expanded the repertoire of medicinal chemists …

Targeted protein degradation refers to the use of small molecules to induce the selective
degradation of proteins. In its most common form, this degradation is achieved through …

Sickle cell disease (SCD) is a prevalent, life-threatening condition attributable to a heritable
mutation in β-hemoglobin. Therapeutic induction of fetal hemoglobin (HbF) can ameliorate …

Lenalidomide, an immunomodulatory drug (IMiD), is commonly used as a first-line therapy in
many haematological cancers, such as multiple myeloma (MM) and 5q myelodysplastic …

The concept of induced protein degradation by small molecules has emerged as a
promising therapeutic strategy that is particularly effective in targeting proteins previously …

Targeted protein degradation (TPD) has emerged as a potentially transformational
therapeutic modality with considerable promise. Molecular glue degraders remodel the …

The ubiquitin-proteasome system (UPS) is the major machinery mediating specific protein
turnover in eukaryotic cells. By ubiquitylating unwanted, damaged, or harmful proteins and …

Targeted protein degraders such as PROTACs and molecular glues are a rapidly emerging
therapeutic modality within industry and academia. Degraders possess unique mechanisms …

The ubiquitin E3 ligase cereblon (CRBN) is the target of therapeutic drugs thalidomide and
lenalidomide and is recruited by most targeted protein degraders (PROTACs and molecular …

Small-molecule chemical “probes” complement the use of molecular biology techniques to
explore, validate, and generate hypotheses on the function of proteins in diseases such as …